Sgl2 inhibitors list
Pro Research Analysisby 
Searched over 200M research papers
Comprehensive List of SGLT2 Inhibitors
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of medications primarily used to manage type 2 diabetes by promoting the excretion of glucose through urine. These drugs have also shown benefits in reducing cardiovascular and renal outcomes. Below is a detailed list of the most commonly studied and utilized SGLT2 inhibitors, along with their key characteristics and clinical implications.
Empagliflozin
Empagliflozin is one of the most extensively studied SGLT2 inhibitors. It has demonstrated significant benefits in reducing the risk of cardiovascular death and hospitalization for heart failure in patients with type 2 diabetes . Empagliflozin has also been shown to reduce the risk of kidney failure, including the need for dialysis or transplantation.
Canagliflozin
Canagliflozin has been evaluated in several major trials, including the CANVAS Program and the CREDENCE study. It has shown efficacy in reducing cardiovascular events and providing renal protection . However, there have been concerns about an increased risk of lower extremity amputations, although recent meta-analyses suggest that the risk may not be as significant as initially thought.
Dapagliflozin
Dapagliflozin has been studied in the DECLARE-TIMI 58 and DAPA-HF trials, showing benefits in reducing heart failure hospitalizations and progression of renal disease . It has also been associated with weight loss and improved glycemic control.
Ertugliflozin
Ertugliflozin is another SGLT2 inhibitor that has been evaluated for its cardiovascular and renal benefits. The VERTIS CV study has shown that it provides similar benefits to other SGLT2 inhibitors in reducing cardiovascular events and protecting kidney function.
Mechanisms of Action and Safety Profile
SGLT2 inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion through urine. This mechanism not only helps in controlling blood sugar levels but also contributes to weight loss and reduced blood pressure . However, these drugs are associated with certain side effects, including an increased risk of genital infections and, in some cases, diabetic ketoacidosis .
Conclusion
SGLT2 inhibitors, including empagliflozin, canagliflozin, dapagliflozin, and ertugliflozin, have proven to be effective in managing type 2 diabetes and providing cardiovascular and renal benefits. While they are generally safe, it is important to monitor for potential side effects such as genital infections and ketoacidosis. The choice of SGLT2 inhibitor should be tailored to the individual patient's risk profile and clinical needs.
Sources and full results
Most relevant research papers on this topic